Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Therapeutic Vaccines Market

ID: MRFR/Pharma/40935-HCR
200 Pages
Satyendra Maurya
Last Updated: April 24, 2026

Therapeutic Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Cancer Vaccines, Infectious Disease Vaccines, Allergy Vaccines, Autoimmune Disease Vaccines), By Administration Route (Intramuscular, Subcutaneous, Intravenous, Oral), By Indication (Prophylactic, Therapeutic), By Target Patient Group (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Therapeutic Vaccines Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Cancer Vaccines | |
      2. 4.1.2 Infectious Disease Vaccines | |
      3. 4.1.3 Allergy Vaccines | |
      4. 4.1.4 Autoimmune Disease Vaccines |
    2. 4.2 Healthcare, BY Administration Route (USD Billion) | |
      1. 4.2.1 Intramuscular | |
      2. 4.2.2 Subcutaneous | |
      3. 4.2.3 Intravenous | |
      4. 4.2.4 Oral |
    3. 4.3 Healthcare, BY Indication (USD Billion) | |
      1. 4.3.1 Prophylactic | |
      2. 4.3.2 Therapeutic |
    4. 4.4 Healthcare, BY Target Patient Group (USD Billion) | |
      1. 4.4.1 Pediatric | |
      2. 4.4.2 Adult | |
      3. 4.4.3 Geriatric |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Moderna (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Pfizer (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 AstraZeneca (GB) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 GSK (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Merck (US) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Bristol-Myers Squibb (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Sanofi (FR) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Roche (CH) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    8. 6.5 US MARKET ANALYSIS BY INDICATION |
    9. 6.6 US MARKET ANALYSIS BY TARGET PATIENT GROUP |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    12. 6.9 CANADA MARKET ANALYSIS BY INDICATION |
    13. 6.10 CANADA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    17. 6.14 GERMANY MARKET ANALYSIS BY INDICATION |
    18. 6.15 GERMANY MARKET ANALYSIS BY TARGET PATIENT GROUP |
    19. 6.16 UK MARKET ANALYSIS BY TYPE |
    20. 6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    21. 6.18 UK MARKET ANALYSIS BY INDICATION |
    22. 6.19 UK MARKET ANALYSIS BY TARGET PATIENT GROUP |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    25. 6.22 FRANCE MARKET ANALYSIS BY INDICATION |
    26. 6.23 FRANCE MARKET ANALYSIS BY TARGET PATIENT GROUP |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY INDICATION |
    30. 6.27 RUSSIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    33. 6.30 ITALY MARKET ANALYSIS BY INDICATION |
    34. 6.31 ITALY MARKET ANALYSIS BY TARGET PATIENT GROUP |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    37. 6.34 SPAIN MARKET ANALYSIS BY INDICATION |
    38. 6.35 SPAIN MARKET ANALYSIS BY TARGET PATIENT GROUP |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY TARGET PATIENT GROUP |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    46. 6.43 CHINA MARKET ANALYSIS BY INDICATION |
    47. 6.44 CHINA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    50. 6.47 INDIA MARKET ANALYSIS BY INDICATION |
    51. 6.48 INDIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    54. 6.51 JAPAN MARKET ANALYSIS BY INDICATION |
    55. 6.52 JAPAN MARKET ANALYSIS BY TARGET PATIENT GROUP |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY INDICATION |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    66. 6.63 THAILAND MARKET ANALYSIS BY INDICATION |
    67. 6.64 THAILAND MARKET ANALYSIS BY TARGET PATIENT GROUP |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY INDICATION |
    71. 6.68 INDONESIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY INDICATION |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY TARGET PATIENT GROUP |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY INDICATION |
    80. 6.77 BRAZIL MARKET ANALYSIS BY TARGET PATIENT GROUP |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    83. 6.80 MEXICO MARKET ANALYSIS BY INDICATION |
    84. 6.81 MEXICO MARKET ANALYSIS BY TARGET PATIENT GROUP |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY INDICATION |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATIENT GROUP |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY INDICATION |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY TARGET PATIENT GROUP, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY TARGET PATIENT GROUP, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Cancer Vaccines
  • Infectious Disease Vaccines
  • Allergy Vaccines
  • Autoimmune Disease Vaccines

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Intramuscular
  • Subcutaneous
  • Intravenous
  • Oral

Healthcare By Indication (USD Billion, 2025-2035)

  • Prophylactic
  • Therapeutic

Healthcare By Target Patient Group (USD Billion, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions